Physical inactivity has consistently been shown to be one of the most powerful, modifiable risk factors for all causes of death and disease, alongside smoking and obesity.
This interactive body map brings together scientific evidence on the links between lack of physical activity and disease.
Click on the coloured dots on the body, or choose a specific disease from the dropdown menu, or cycle through all diseases via the next and previous buttons.
To use the map, click on any of the coloured dots on the body, or choose a specific disease from the dropdown menu. You can also filter by disease or condition type.
This is the first in our package on the benefits of exercise. Read other articles in the package here.
For a copy of the data and notes on the methodology used for the calculations, please visit The Conversation’s GitHub page.
Carol Maher receives funding from the National Health and Medical Research Council and the National Heart Foundation.
Tim Olds receives funding from the ARC and the NHMRC.
This article was originally published on The Conversation. Read the original article.


Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition 



